webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine

  CAS No.: 175724-30-8   Cat No.: BADC-00991   Purity: >98.0% HNMR MS 4.5  

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine

Structure of 175724-30-8

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C25H47NO9
Molecular Weight
505.64
Shipping
Room temperature, or blue ice upon request.
Storage
Store at -20 °C, keep in dry and avoid sunlight.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
5 g $1573 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane; tert-butyl 3,3'-(2-amino-2-((3-tert-butoxy-3-oxopropoxy)methyl)propane-1,3-diyl)bis(oxy)dipropanoate
IUPAC Name
tert-butyl 3-[2-amino-3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropoxy]-2-[[3-[(2-methylpropan-2-yl)oxy]-3-oxopropoxy]methyl]propoxy]propanoate
Canonical SMILES
CC(C)(C)OC(=O)CCOCC(COCCC(=O)OC(C)(C)C)(COCCC(=O)OC(C)(C)C)N
InChI
InChI=1S/C25H47NO9/c1-22(2,3)33-19(27)10-13-30-16-25(26,17-31-14-11-20(28)34-23(4,5)6)18-32-15-12-21(29)35-24(7,8)9/h10-18,26H2,1-9H3
InChIKey
KPXODPHVWBQJEG-UHFFFAOYSA-N
Solubility
10 mm in DMSO
PSA
132.61000
Appearance
Colourless oil
Shelf Life
-20°C 3 years powder; -80°C 2 years in solvent
Shipping
Room temperature, or blue ice upon request.
Storage
Store at -20 °C, keep in dry and avoid sunlight.

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine is a multifunctional ADC linker widely utilized in antibody-drug conjugate development. Its structure features three tert-butoxycarbonyl (Boc)-protected ethoxy groups connected to a central amine, providing multiple sites for controlled payload attachment. In ADC linker design, this architecture allows for the precise conjugation of ADC cytotoxins while maintaining chemical stability under physiological conditions, supporting efficient and reproducible bioconjugation strategies.

The Boc-protected functional groups facilitate selective deprotection and subsequent coupling reactions, enabling attachment of diverse ADC payloads, including microtubule inhibitors, DNA-damaging agents, and other potent cytotoxins. The tris-functional design introduces a degree of spatial separation between conjugated payloads, reducing steric interference with antibody-antigen interactions and enhancing the solubility and overall stability of the resulting ADC.

In ADC payload applications, Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine supports site-specific conjugation and controlled drug-to-antibody ratios (DAR), which are critical for optimizing pharmacokinetics and therapeutic efficacy. Its structural flexibility allows researchers to design complex ADC architectures, including multi-payload conjugates, while maintaining antibody functionality and reducing aggregation tendencies.

This ADC linker is widely applied in oncology-focused bioconjugation workflows, where chemical robustness, linker versatility, and controlled reactivity are essential. The combination of Boc protection, tris-functional architecture, and hydrophilic ethoxy spacers provides a reliable platform for constructing high-performance antibody-drug conjugates with reproducible linker stability, efficient payload delivery, and optimized therapeutic potential.

What is Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine?

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine is a multifunctional linker widely used in ADC construction. It provides steric protection and enhanced solubility while offering functional groups suitable for conjugation to antibodies and cytotoxic payloads in targeted drug delivery applications.

7/7/2019

We are interested in how Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine improves ADC stability.

The structural design of Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine reduces steric hindrance and prevents premature cleavage. Its chemical stability under physiological conditions ensures controlled release of the payload, which is critical for maintaining ADC efficacy and minimizing off-target toxicity.

5/9/2019

Could you provide the recommended storage conditions for Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine?

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine should be stored at low temperatures, typically -20°C, in a dry and inert atmosphere to prevent moisture-induced hydrolysis and maintain its structural integrity over extended periods.

19/2/2019

Dear Sir, may I ask if certificates of analysis are available for Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine?

Yes, BOC Sciences provides comprehensive documentation including certificates of analysis (CoA) that cover identity, structural verification, and analytical characterization to support regulatory submissions and quality control processes.

28/6/2020

Dear team, what analytical methods are recommended for Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine?

Analytical verification can be performed using NMR spectroscopy, LC-MS, and HPLC techniques. These methods ensure structural integrity and functional group availability for subsequent conjugation reactions.

9/8/2021

— Dr. Jonathan White, Medicinal Chemist (UK)

This complex linker performed exceptionally well in our ADC synthesis. Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine maintained integrity under challenging reaction conditions.

19/2/2019

— Ms. Clara Hoffmann, Biochemist (Germany)

BOC Sciences provided Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine with detailed QC, ensuring reproducible results in our multi-step synthesis.

9/8/2021

— Dr. William Parker, Senior Scientist (USA)

Excellent solubility and stability of this linker facilitated efficient conjugation and minimized side reactions.

28/6/2020

— Dr. Elise Moreau, Chemist (France)

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine allowed high-yield synthesis of our ADC intermediates, saving time and resources.

7/7/2019

— Mr. Noah Brown, Bioconjugation Specialist (Canada)

The technical team assisted us in optimizing Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine usage, enhancing reproducibility.

— Dr. Isabella Taylor, Senior Researcher (USA)

High-quality product with consistent lot-to-lot performance enabled smooth workflow in our ADC pipeline.

5/9/2019

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Methyltetrazine-amino-PEG3-CH2CH2NHBoc | Methyltetrazine-amino-PEG8-CH2CH2NHBoc | Methyltetrazine-amino-PEG4-CH2CH2NHBoc | Methyltetrazine-PEG12-NHS ester | ATFB-SE | MAL-Di-EG-OPFP | MC-Val-Ala-PAB-PNP | diSPhMC-Asn-Pro-Val-PABC-MMAE | Trastuzumab emtansine | MC-Gly-Gly-Phe | Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine
Send Inquiry
Verification code
Inquiry Basket